Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...

Eli Lilly's experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight.

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a ...

Hengrui's GLP-1/GIP drug shows 22.8% weight loss at 36 weeks in Phase 2, beating Eli Lilly's retatrutide. Kailera ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

The use of GLP-1 drugs sparked the term "Ozempic shaming" to describe the negative perceptions faced by those who choose medical interventions for weight management. Some critics argue that using the ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...